US5204113A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions containing pentamidine
Assignee: Fisons Ltd
•
Filing: 1988-04-08
•
Granted: 1993-04-20
•
Expires: 2008-04-08
Abstract
Abstract Pharmaceutical compositions suitable for administration by inhalation and containing pentamidine, or pharmaceutically acceptable salt thereof, in powder form. Such compositions include pressurized aerosol compositions and non-pressurized powder compositions. Also described is finely divided powdered pentamidine with a mass median diameter in the range 0.01 to 10 microns and a method for the prevention or treatment of pneumacystics carinii pneumonia which comprises administration by inhalation to a patient having or susceptible to that condition of a therapeutically effective quantity of pentamidine, or a pharmaceutically acceptable salt thereof, in powder form.
Inventors
- 👤 Philip S. Hartley
- 👤 John Stevens
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 11:12
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/0075; A61K31/00; A61K31/13; A61K31/155; A61K9/008
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
52 words
A sealed capsule loosely filled with a nonpressurized dry powder pharmaceutical composition for the prophylactic or remedial treatment of pneumono-cystis carinii pneumonia by oral or nasal inhalation, said composition containing as active ingredient, finely divided pentamidine or a pharmaceutically acceptable salt thereof with a mass median diameter of 0.01 to 10 microns.
Claim 2
Dependent Claim
52 words
A sealed capsule loosely filled with a nonpressurized dry powder pharmaceutical composition for the prophylactic or remedial treatment of pneumono-cystis carinii pneumonia by oral or nasal inhalation, said composition containing as active ingredient, finely divided pentamidine or a pharmaceutically acceptable salt thereof with a mass median diameter of 0.01 to 10 microns.
Claim 3
Dependent Claim
18 words
A composition according to claim 1, wherein the active ingredient is in admixture with a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
16 words
A composition according to claim 1 which contains from 2 to 50% by weight active ingredient.
Claim 5
Dependent Claim
29 words
A composition according to claim 1, wherein at least 95% by weight of the particles of active ingredient have an effective particle size of from 0.01 to 10 microns.
Claim 6
Dependent Claim
43 words
A method for the prevention or treatment of pneumono-cystis carinii pneumonia which comprises administration by oral or nasal inhalation of a therapeutically effective quantity of a dry powder composition in accordance with claim 1, to a patient having or susceptible to that condition.
References Cited (Backward Citations)
US3957965A
Cited
FR8142M
Cited
US3888253A
Cited
US3870046A
Cited
US4013075A
Cited
US3948264A
Cited
US4161516A
Cited
US4073922A
Cited
US4119723A
Cited
US4563468A
Cited
US4399151A
Cited
US4324794A
Cited
US4397863A
Cited
US4681752A
Cited
US4590206A
Cited
US4619942A
Cited
US4823784B1
Cited
US4823784A
Cited
US4426384A
Cited
US4402965A
Cited
US4546113A
Cited
US4649911A
Cited
DE3533494A1
Cited
US4781871A
Cited
US4752425A
Cited
EP0292100A1
Cited
EP0309519A1
Cited
WO1988007855A1
Cited
US4956355A
Cited
US5106837A
Cited
US4981874A
Cited
US5026687A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-19 | 1996-10-19 | 1997-04-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-19 | 2000-10-19 | 2001-04-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-19 | 2004-10-19 | 2005-04-20 | $7700.00 | Window Closed / Lapsed |